The pan-Canadian Pharmaceutical Alliance Corporation (pCPA) Annual General Meeting
To be held at 2125 Victoria Avenue, Regina, SK. S4P 0S3 on October 25, 2023 at 5 p.m. CST
Notice is hereby given that the first Annual General Meeting of the members of the pan-Canadian Pharmaceutical Alliance Corporation (pCPA) will take place on Wednesday, October 25, 2023 at 5 p.m. CST. Members may participate in person or virtually.
The new three-year pricing initiative for generic drugs will come into effect on October 1, 2023.
The agreement between the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA) builds upon the successes achieved to date with the pan-Canadian Generic Tiered Pricing Framework (TPF) and the pan-Canadian molecules.
The pan-Canadian Pharmaceutical Alliance’s (pCPA) Board of Directors is excited to announce that Douglas Clark will become the first CEO of the newly incorporated organization, effective September 11, 2023.
The pan-Canadian Pharmaceutical Alliance is pleased to announce that our transition to a stand-alone organization is now complete.
The pCPA is accepting feedback regarding the development of a set of principles and conditions that will inform the negotiation process and potential product listing agreements for any drug products that follow the CADTH time-limited recommendation pathway.
The pCPA continues the transition to a stand-alone organization with the expectation that this process will be completed in the summer.
The pan-Canadian Pharmaceutical Alliance is continuing the transition to a stand-alone organization including recruiting key leaders and ensuring all necessary operational supports are in place.
Working with the global executive search firm Odgers Berndtson, the pan-Canadian Pharmaceutical Alliance (pCPA) is recruiting a chief executive officer as it continues its transition to a stand-alone organization. The new CEO is expected to be in place this spring. Read the full update.